RLMD News and Press, Relmada Therapeutics Inc. From 02/26/24

2024-02-26 19:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-01 10:00:10 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-02-01 08:38:25 ET Blackboxstocks  ( BLBX ) +45% Acquisition Target Evtec Aluminium Receives New $67 Million Long Term Supply Contract from Jaguar Land Rover. FibroBiologics  ( FBLG ) +44% goes public through direct listing on Nasdaq. Nextrack...

2024-01-14 03:33:27 ET Summary Relmada Therapeutics is developing REL-1017, a therapy for CNS diseases that targets hyperactive GluN2D channels in NMDA receptors. Phase 2 trial showed a rapid and sustained antidepressant effect in patients who did not respond to standard antidepre...

2024-01-04 12:34:16 ET More on Mid-day movers & Stocks. Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024 Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32 ...

Relmada Therapeutics Provides Corporate Update PR Newswire Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated Relmada's Strong Balance Sheet to Support the Company Through All of 2024's Expected Critical Catalysts ...

Relmada Therapeutics Inc. (RLMD) is expected to report $-0.95 for Q3 2023

2023-11-09 02:56:01 ET Relmada Therapeutics, Inc. (RLMD) Q3 2023 Results Earnings Conference Call November 9, 2023, 04:30 PM ET Company Participants Tim McCarthy - Investor Relations, Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Finan...

2023-11-08 16:17:54 ET More on Relmada Therapeutics Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024 For further details see: Relmada Therapeutics GAAP EPS of -$0.73

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results PR Newswire CORAL GABLES, Fla. , Nov. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the ...